VG Life Sciences Inc. (VGLS)

[Eddie2468]

We shall see, but don't be surprised if I win this bet. We both know VG will need money. As shown in the Form 10, DMBM is almost paid off and may be by now. The last time money was received from DMBM was March 2013, as far as a Convertible Note, so I'm pretty sure borrowing from DMBM is over.

Now where will VG also look for money to fund the future. I think it will come from a partnership and from Big Pharma.

With licensing deals put together with milestone royalties, don't be surprised if it happens.

Notice the last paragraph I copy and paste. 10 million upfront for two pre-clinical programs.

http://www.manufacturingchemist.com/news/article_page/Drug_licensing_deals_in_2010/58641

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms.

Licensing deals have become an important strategy for big pharma companies looking to fill their development pipelines, a strategy that also provides a lifeline to biotech companies as it gives them much-needed cash to keep their business alive. This is often structured as a technology access fee, providing cash up-front, followed by milestone payments to mark successes and royalties on sales if the product ultimately makes it onto the market.

Another important therapeutic area research-wise is respiratory disease. Here, Johnson & Johnson has licensed two advanced small molecule preclinical programmes in asthma and COPD from Sweden’s Orexo, plus another for an undisclosed indication. The initial deal is for three years and Orexo’s research will be funded to the tune of up to $21.5m, $10m of it upfront. It could ultimately be worth more than $550m plus royalties.